SAFETY DATA SHEET

Buprenorphine Liquid Formulation

Section 1: Identification

Product name: Buprenorphine Liquid Formulation

Manufacturer or supplier's details
Company: MSD
Address: 33 Whakatiki Street - Private Bag 908
         Upper Hutt - New Zealand
Telephone: 908-740-4000
Emergency telephone number: 1-908-423-6000
E-mail address: EHSDATASTEWARD@msd.com
Telefax: 908-735-1496

Recommended use of the chemical and restrictions on use
Recommended use: Pharmaceutical

Section 2: Hazard identification

GHS Classification
Not a hazardous substance or mixture.

GHS label elements
Not a hazardous substance or mixture.

Other hazards which do not result in classification
None known.

Section 3: Composition/information on ingredients

Substance / Mixture: Mixture

Components

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Buprenorphine Hydrochloride</td>
<td>53152-21-9</td>
<td>&lt; 0.3</td>
</tr>
</tbody>
</table>

Section 4: First-aid measures

If inhaled: If inhaled, remove to fresh air.
Get medical attention if symptoms occur.

In case of skin contact: Wash with water and soap as a precaution.
Get medical attention if symptoms occur.

In case of eye contact: Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting.
Get medical attention if symptoms occur.
SAFETY DATA SHEET

Buprenorphine Liquid Formulation

Most important symptoms and effects, both acute and delayed
Rinse mouth thoroughly with water.

Protection of first-aiders
No special precautions are necessary for first aid responders.

Notes to physician
Treat symptomatically and supportively.

Section 5: Fire-fighting measures

Suitable extinguishing media
Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media
None known.

Specific hazards during firefighting
Exposure to combustion products may be a hazard to health.

Hazardous combustion products
Carbon oxides

Specific extinguishing methods
Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.
Use personal protective equipment.

Section 6: Accidental release measures

Personal precautions, protective equipment and emergency procedures
Follow safe handling advice and personal protective equipment recommendations.

Environmental precautions
Discharge into the environment must be avoided.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g. by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up
Soak up with inert absorbent material.
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding
**SAFETY DATA SHEET**

**Buprenorphine Liquid Formulation**

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue</th>
<th>Date of first issue</th>
</tr>
</thead>
</table>

Certain local or national requirements.

**Section 7: Handling and storage**

**Technical measures**: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

**Local/Total ventilation**: Use only with adequate ventilation.

**Advice on safe handling**: Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Take care to prevent spills, waste and minimize release to the environment.

**Hygiene measures**: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

**Conditions for safe storage**: Keep in properly labelled containers. Store in accordance with the particular national regulations.

**Materials to avoid**: Do not store with the following product types: Strong oxidizing agents

**Section 8: Exposure controls/personal protection**

**Components with workplace control parameters**

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Buprenorphine Hydrochloride</td>
<td>53152-21-9</td>
<td>TWA</td>
<td>0.2 µg/m³ (OEB 5)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wipe limit</td>
<td>2 µg/100 cm²</td>
<td>Internal</td>
</tr>
</tbody>
</table>

**Engineering measures**: Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace. All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. No open handling permitted. Totally enclosed processes and materials transport systems are required. Operations require the use of appropriate containment technology designed to prevent leakage of compounds into the workplace.

**Personal protective equipment**

**Respiratory protection**: No personal respiratory protective equipment normally re-
SAFETY DATA SHEET
Buprenorphine Liquid Formulation

Hand protection
Material: Chemical-resistant gloves
Remarks: Consider double gloving.
Eye protection: Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection: Work uniform or laboratory coat.
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentially contaminated clothing.

Section 9: Physical and chemical properties
Appearance: liquid
Colour: No data available
Odour: No data available
Odour Threshold: No data available
pH: No data available
Melting point/freezing point: No data available
Initial boiling point and boiling range: No data available
Flash point: No data available
Evaporation rate: No data available
Flammability (solid, gas): Not applicable
Flammability (liquids): No data available
Upper explosion limit / Upper flammability limit: No data available
Lower explosion limit / Lower flammability limit: No data available
Vapour pressure: No data available
Relative vapour density: No data available
Relative density: No data available
SAFETY DATA SHEET

Buprenorphine Liquid Formulation

Density : No data available

Solubility(ies)
   Water solubility : No data available

Partition coefficient: n-octanol/water : Not applicable

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity
   Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Particle size : Not applicable

Section 10: Stability and reactivity

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : Can react with strong oxidizing agents.

Conditions to avoid : None known.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

Section 11: Toxicological information

Exposure routes : Inhalation
   Skin contact
   Ingestion
   Eye contact

Acute toxicity
Not classified based on available information.

Components:

Buprenorphine Hydrochloride:

Acute oral toxicity : LD50 (Mouse): 261 mg/kg
   LD50 (Rat): 600 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Acute toxicity (other routes of) : LD50 (Rat): 31 mg/kg
Skin corrosion/irritation
Not classified based on available information.

Components:
Buprenorphine Hydrochloride:
Remarks : No data available

Serious eye damage/eye irritation
Not classified based on available information.

Components:
Buprenorphine Hydrochloride:
Remarks : No data available

Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Components:
Buprenorphine Hydrochloride:
Remarks : No data available

Chronic toxicity

Germ cell mutagenicity
Not classified based on available information.

Components:
Buprenorphine Hydrochloride:
Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: equivocal

Test Type: Chromosomal aberration
Result: negative

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
Result: positive

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.
Carcinogenicity
Not classified based on available information.

Components:

Buprenorphine Hydrochloride:
Species: Rat
Application Route: Oral
Exposure time: 27 Months
LOAEL: 56 mg/kg body weight
Result: positive
Target Organs: Testes
Remarks: The significance of these findings for humans is not certain.

Species: Mouse
Application Route: Oral
Exposure time: 86 weeks
NOAEL: 100 mg/kg body weight
Result: negative

Carcinogenicity - Assessment: Weight of evidence does not support classification as a carcinogen

Reproductive toxicity
Not classified based on available information.

Components:

Buprenorphine Hydrochloride:
Effects on fertility: Test Type: Fertility
Species: Rat
Application Route: Oral
Fertility: NOAEL: 80 mg/kg body weight
Result: No effects on fertility

Test Type: Fertility
Species: Rat
Application Route: Subcutaneous
Fertility: NOAEL: 5 mg/kg body weight
Result: No effects on fertility

Test Type: Fertility
Species: Rabbit
Application Route: Oral
Fertility: LOAEL: 1 mg/kg body weight
Result: Preimplantation loss

Test Type: Fertility
Species: Rabbit
Application Route: Intravenous
Fertility: LOAEL: 0.2 mg/kg body weight
Result: Postimplantation loss.
| Test Type: Development | Species: Rat | Application Route: Subcutaneous | Developmental Toxicity: LOAEL: 5 mg/kg body weight | Result: Embryo-foetal toxicity, No teratogenic effects, Skeletal malformations |
| Test Type: Development | Species: Rat | Application Route: Oral | Developmental Toxicity: NOAEL: 160 mg/kg body weight | Result: No effects on foetal development |
| Test Type: Development | Species: Rat | Application Route: Subcutaneous | Developmental Toxicity: LOAEL: 0.1 mg/kg body weight | Result: Effects on newborn |
| Test Type: Development | Species: Rabbit | Application Route: Intramuscular | Developmental Toxicity: LOAEL: 5 mg/kg body weight | Result: Embryo-foetal toxicity, Skeletal malformations |
| Test Type: Development | Species: Rabbit | Application Route: Oral | Developmental Toxicity: LOAEL: 1 mg/kg body weight | Result: Embryo-foetal toxicity, Skeletal malformations |

Reproductive toxicity - Assessment:
May damage the unborn child. Suspected of damaging fertility.

**STOT - single exposure**
Not classified based on available information.

**Components:**

**Buprenorphine Hydrochloride:**
Assessment:
May cause drowsiness or dizziness.

**STOT - repeated exposure**
Not classified based on available information.

**Aspiration toxicity**
Not classified based on available information.

**Experience with human exposure**

**Components:**

**Buprenorphine Hydrochloride:**
Inhalation:
Target Organs: Central nervous system
Symptoms: Drowsiness, sedation, Headache, Nausea, Vomiting.
ing, Dizziness, Vertigo, Sweating, constipation, insomnia, Pain, respiratory depression, constriction of pupils, decrease in heart rate, Lowered blood pressure
Remarks: May cause neonatal withdrawal

Section 12: Ecological information

Ecotoxicity

Components:

Buprenorphine Hydrochloride:

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): 6.25 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 0.319 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 0.137 mg/l
Exposure time: 28 d
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0.883 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211

LOEC (Daphnia magna (Water flea)): 1.95 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211

Toxicity to microorganisms : EC50: 588 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

NOEC: 135 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Persistence and degradability

Components:

Buprenorphine Hydrochloride:

Biodegradability : Result: Not readily biodegradable.
Bioaccumulative potential

**Components:**

**Buprenorphine Hydrochloride:**

Bioaccumulation: Species: Oncorhynchus mykiss (rainbow trout)
Bioconcentration factor (BCF): 0.4
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water: log Pow: 3.11

**Mobility in soil**

**Components:**

**Buprenorphine Hydrochloride:**

Distribution among environmental compartments: log Koc: 4.11

Other adverse effects: No data available

Section 13: Disposal considerations

Disposal methods

Waste from residues: Dispose of in accordance with local regulations.
Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

Section 14: Transport information

International Regulations

UNRTDG
Not regulated as a dangerous good

IATA-DGR
Not regulated as a dangerous good

IMDG-Code
Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

National Regulations

NZS 5433
Not regulated as a dangerous good

Section 15: Regulatory information

Safety, health and environmental regulations/legislation specific for the substance or mixture
SAFETY DATA SHEET

Buprenorphine Liquid Formulation

Version 1.7 Revision Date: 13.09.2019 SDS Number: 745000-00008 Date of last issue: 24.04.2019
Date of first issue: 08.06.2016

HSNO Approval Number
Not applicable

HSW Controls
Certified handler certificate not required.
Tracking hazardous substance not required.
Refer to the Health and Safety at Work (Hazardous Substances) Regulations 2017, for further information.

The components of this product are reported in the following inventories:

AICS : not determined
DSL : not determined
IECSC : not determined

Section 16: Other information

Further information

Date format: dd.mm.yyyy

Full text of other abbreviations

AICS - Australian Inventory of Chemical Substances; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temper-
The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.